Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹13.04Prev. Close
₹12.92Turnover(Lac.)
₹258.48Day's High
₹13.05Day's Low
₹12.752 Week's High
₹18.6552 Week's Low
₹7.1Book Value
₹2.97Face Value
₹1Mkt Cap (₹ Cr.)
1,202.26P/E
51.2EPS
0.25Divi. Yield
09 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
14 Aug 2023
12:00 AM
AGM
Announcement Date: 14 Aug, 2023
16 Aug 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 94 | 91.29 | 88.75 | 78.07 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 162.01 | 130.94 | 98.84 | 67.58 |
Net Worth | 256.01 | 222.23 | 187.59 | 145.65 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 244.8 | 205.51 | 158.63 | 184.82 |
yoy growth (%) | 19.12 | 29.55 | -14.17 | 0.5 |
Raw materials | -161.46 | -151.62 | -108.94 | -128.11 |
As % of sales | 65.95 | 73.77 | 68.68 | 69.31 |
Employee costs | -19.66 | -16.29 | -15.04 | -14.49 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 40.67 | 17.34 | 12.11 | 16 |
Depreciation | -4.03 | -4.06 | -3.72 | -3.12 |
Tax paid | -11.53 | -3.03 | -3.36 | -5.34 |
Working capital | 84.97 | 9.2 | 8.52 | 11.14 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.12 | 29.55 | -14.17 | 0.5 |
Op profit growth | 127.39 | 42.55 | -28.62 | -1.5 |
EBIT growth | 130.01 | 43.76 | -24.08 | 0.23 |
Net profit growth | 104.66 | 64.83 | -18.82 | 2.86 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|---|
Gross Sales | 263.39 | 224.25 | 219.66 | 182.75 | 181.9 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 263.39 | 224.25 | 219.66 | 182.75 | 181.9 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 13.53 | 14.61 | 12.02 | 4.86 | 4.66 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,524.95 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,562 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,484.45 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,092.9 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,488 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
Kedarmal Bankda
Managing Director
Vijay Shankarlal Bankda
Independent Director
Vinod Kumar Kabra
Independent Director
Krishna Das Neema
Independent Director
Praveen Jindal
Whole-time Director
Rinki Bankda
Independent Director
Ruchi Jindal
Company Sec. & Compli. Officer
Vaishali Agrawal
Independent Director
Ritesh Kumar Lunkad
Independent Director
Ankit Jain
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Syncom Formulations (India) Ltd
Summary
Incorporated as a private limited company in 1988, Syncom Formulations (India) Limited was converted into a public limited company in Jun.92. The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards. Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda.In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis.In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.94 was completed in 1995.During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range
Read More
What is the Syncom Formulations (India) Ltd share price today?
The Syncom Formulations (India) Ltd shares price on nse is Rs.₹12.79 today.
What is the Market Cap of Syncom Formulations (India) Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Syncom Formulations (India) Ltd is ₹1202.26 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Syncom Formulations (India) Ltd?
The PE and PB ratios of Syncom Formulations (India) Ltd is 51.2 and 4.20 as of 03 Jul ‘24
What is the 52 Week High and Low of Syncom Formulations (India) Ltd?
The 52-week high/low is the highest and lowest price at which a Syncom Formulations (India) Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Syncom Formulations (India) Ltd is ₹7.1 and ₹18.65 as of 03 Jul ‘24
What is the CAGR of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at 72.27%, 6 Month at -19.00%, 3 Month at 5.47% and 1 Month at 8.12%.
What is the shareholding pattern of Syncom Formulations (India) Ltd?
The shareholding pattern of Syncom Formulations (India) Ltd is as follows:
Promoters - 50.57 %
Institutions - 0.08 %
Public - 49.35 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
